These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 24439967)

  • 1. Biomarkers for the prognosis of pulmonary arterial hypertension: Holy Grail or flying circus?
    Lador F; Soccal PM; Sitbon O
    J Heart Lung Transplant; 2014 Apr; 33(4):341-3. PubMed ID: 24439967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An exploratory panel of biomarkers for risk prediction in pulmonary hypertension: emerging role of CT-proET-1.
    Silva Marques J; Martins SR; Calisto C; Gonçalves S; Almeida AG; de Sousa JC; Pinto FJ; Diogo AN
    J Heart Lung Transplant; 2013 Dec; 32(12):1214-21. PubMed ID: 23916896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of serial N-terminal pro-B-type natriuretic peptide measurements for determining prognosis in patients with pulmonary arterial hypertension.
    Mauritz GJ; Rizopoulos D; Groepenhoff H; Tiede H; Felix J; Eilers P; Bosboom J; Postmus PE; Westerhof N; Vonk-Noordegraaf A
    Am J Cardiol; 2011 Dec; 108(11):1645-50. PubMed ID: 21890089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension.
    Andreassen AK; Wergeland R; Simonsen S; Geiran O; Guevara C; Ueland T
    Am J Cardiol; 2006 Aug; 98(4):525-9. PubMed ID: 16893710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological serum markers in the management of pediatric pulmonary arterial hypertension.
    Van Albada ME; Loot FG; Fokkema R; Roofthooft MT; Berger RM
    Pediatr Res; 2008 Mar; 63(3):321-7. PubMed ID: 18287971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The value of brain natriuretic peptide in connective tissue diseases associated with pulmonary arterial hypertension].
    Tian Z; Guo XX; Li MT; Wang Q; Liu YT; Zhao JL; Fang Q; Zeng XF
    Zhonghua Nei Ke Za Zhi; 2011 Feb; 50(2):102-6. PubMed ID: 21418827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension.
    Mathai SC; Bueso M; Hummers LK; Boyce D; Lechtzin N; Le Pavec J; Campo A; Champion HC; Housten T; Forfia PR; Zaiman AL; Wigley FM; Girgis RE; Hassoun PM
    Eur Respir J; 2010 Jan; 35(1):95-104. PubMed ID: 19643943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis.
    Allanore Y; Borderie D; Avouac J; Zerkak D; Meune C; Hachulla E; Mouthon L; Guillevin L; Meyer O; Ekindjian OG; Weber S; Kahan A
    Arthritis Rheum; 2008 Jan; 58(1):284-91. PubMed ID: 18163505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic testing and blood biomarkers in paediatric pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK.
    Pattathu J; Gorenflo M; Hilgendorff A; Koskenvuo JW; Apitz C; Hansmann G; Alastalo TP
    Heart; 2016 May; 102 Suppl 2():ii36-41. PubMed ID: 27053696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension.
    Nickel N; Golpon H; Greer M; Knudsen L; Olsson K; Westerkamp V; Welte T; Hoeper MM
    Eur Respir J; 2012 Mar; 39(3):589-96. PubMed ID: 21885392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venous endotelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension.
    Vizza CD; Letizia C; Petramala L; Badagliacca R; Poscia R; Zepponi E; Crescenzi E; Nona A; Benedetti G; Ferrante F; Sciomer S; Fedele F
    Regul Pept; 2008 Nov; 151(1-3):48-53. PubMed ID: 18796317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Left heart disease: a frequent cause of early pulmonary hypertension in systemic sclerosis, unrelated to elevated NT-proBNP levels or overt cardiac fibrosis but associated with increased levels of MR-proANP and MR-proADM: retrospective analysis of a French Canadian cohort.
    Miller L; Chartrand S; Koenig M; Goulet JR; Rich É; Chin AS; Chartrand-Lefebvre C; Abrahamowicz M; Senécal JL; Grodzicky T
    Scand J Rheumatol; 2014; 43(4):314-23. PubMed ID: 25089008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential of biomarkers in pulmonary arterial hypertension.
    Cracowski JL; Leuchte HH
    Am J Cardiol; 2012 Sep; 110(6 Suppl):32S-38S. PubMed ID: 22921030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of the REVEAL pulmonary arterial hypertension prediction model using non-invasive and routinely measured parameters.
    Cogswell R; Pritzker M; De Marco T
    J Heart Lung Transplant; 2014 Apr; 33(4):382-7. PubMed ID: 24534251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NT-proBNP reflects right ventricular structure and function in pulmonary hypertension.
    Gan CT; McCann GP; Marcus JT; van Wolferen SA; Twisk JW; Boonstra A; Postmus PE; Vonk-Noordegraaf A
    Eur Respir J; 2006 Dec; 28(6):1190-4. PubMed ID: 16971413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ghrelin and its relation with N-terminal brain natriuretic peptide, endothelin-1 and nitric oxide in patients with idiopathic pulmonary hypertension.
    Yang D; Liu Z; Yang Z
    Cardiology; 2013; 124(4):241-5. PubMed ID: 23571554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-terminal pro brain natriuretic peptide in arterial hypertension--a marker for left ventricular dimensions and prognosis.
    Hildebrandt P; Boesen M; Olsen M; Wachtell K; Groenning B
    Eur J Heart Fail; 2004 Mar; 6(3):313-7. PubMed ID: 14987582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of plasma endothelin-1 level after bosentan administration in pulmonary arterial hypertension.
    Hiramoto Y; Shioyama W; Higuchi K; Arita Y; Kuroda T; Sakata Y; Nakaoka Y; Fujio Y; Yamauchi-Takihara K
    J Cardiol; 2009 Jun; 53(3):374-80. PubMed ID: 19477379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline NT-proBNP correlates with change in 6-minute walk distance in patients with pulmonary arterial hypertension in the pivotal inhaled treprostinil study TRIUMPH-1.
    Frantz RP; McDevitt S; Walker S
    J Heart Lung Transplant; 2012 Aug; 31(8):811-6. PubMed ID: 22759797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B-type natriuretic peptide and C-terminal-pro-endothelin-1 for the prediction of severely impaired peak oxygen consumption.
    Maeder MT; Brutsche MH; Staub D; Morgenthaler NG; Bergmann A; Noveanu M; Laule K; Breidthardt T; Christ A; Klima T; Reichlin T; Potocki M; Mueller C
    J Intern Med; 2009 May; 265(5):604-15. PubMed ID: 19226375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.